Evidence-Based Medicine Guidelines
Intravenous immunoglobulin (IVIg) as adjuvant therapy for Wegener's granulomatosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Intravenous Immunoglobulin (IVIg) as Adjuvant Therapy for Wegener's Granulomatosis." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/456932/all/Intravenous_immunoglobulin__IVIg__as_adjuvant_therapy_for_Wegener's_granulomatosis.
Intravenous immunoglobulin (IVIg) as adjuvant therapy for Wegener's granulomatosis. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/456932/all/Intravenous_immunoglobulin__IVIg__as_adjuvant_therapy_for_Wegener's_granulomatosis. Accessed November 28, 2023.
Intravenous immunoglobulin (IVIg) as adjuvant therapy for Wegener's granulomatosis. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/456932/all/Intravenous_immunoglobulin__IVIg__as_adjuvant_therapy_for_Wegener's_granulomatosis
Intravenous Immunoglobulin (IVIg) as Adjuvant Therapy for Wegener's Granulomatosis [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 November 28]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/456932/all/Intravenous_immunoglobulin__IVIg__as_adjuvant_therapy_for_Wegener's_granulomatosis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Intravenous immunoglobulin (IVIg) as adjuvant therapy for Wegener's granulomatosis
ID - 456932
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/456932/all/Intravenous_immunoglobulin__IVIg__as_adjuvant_therapy_for_Wegener's_granulomatosis
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
